SVB Leerink Prometheus Biosciences Prices Upsized $190M IPO The company is focused on developing and commercializing therapeutic and companion diagnostic products to treat inflammatory bowel disease. M&A Deals in MDx/Omics Research Tools Space Fall 13 Percent in 2020 Premium Although the total number of deals went down in 2020, those deals were worth more compared to 2019 — four of the top five had billion-dollar price tags. SVB Leerink Initiates Coverage of Twist Bioscience With Market Perform Rating The synbio company offers scale and lower costs in "massive" end markets, SVB Leerink analysts said, and could soon command an even more attractive valuation. First Analysis Upgrades NeoGenomics to Strong Buy After Stock Dips The company's Q4 revenues exceeded Wall Street estimates and the clinical genetic testing and pharma services businesses outperformed expectations. Investment Banks Initiate Coverage of Centogene With Bullish Outlooks BTIG gave Centogene a Buy rating, while SVB Leerink and Evercore ISI each gave the company an Outperform rating. Jul 26, 2018 Veracyte Prices $51.3M Public Offering Jan 2, 2018 Cowen, Leerink, JP Morgan Initiate Coverage of Quanterix Apr 17, 2017 Leerink Initiates Coverage of Exact Sciences With Outperform Rating Oct 1, 2015 Leerink Downgrades Illumina to Market Perform on Near-Term Growth Uncertainties May 14, 2015 Leerink Upgrades Invitae to Outperform Mar 18, 2015 Leerink Upgrades T2 Bio Shares to Outperform Jan 16, 2015 Leerink Downgrades Foundation Medicine to Market Perform Apr 14, 2014 Leerink Swann Upgrades Fluidigm to Outperform Apr 29, 2013 Leerink Swann Downgrades Fluidigm, Noting Company's Shares May Take 'A Breather' Apr 16, 2013 Survey Offers 'Cautious Array Forecast' for Illumina as Sequencing, Affymetrix Products Gain Ground Premium Jan 3, 2013 Leerink Swann Downgrades Waters, Noting Macroeconomic Environment and Soft End Markets Jul 18, 2012 MDx Finding Traction in European Labs, Leerink Swann Says Jan 26, 2012 Leerink Swann Upgrades Life Technologies to Outperform Apr 12, 2011 Leerink Swann Lowers Estimate for Illumina's Q1 Revenues, EPS Mar 22, 2011 Analysts Predict 'Muted' Array Demand in 2011, Cut Expectations for Illumina Premium Feb 10, 2011 Fluidigm Sets IPO Pricing at $13.50 per Share Premium Jan 31, 2011 Demand Steady for LS Tools in US Academic Market, Investment Bank Says Jan 7, 2011 Caliper Downgraded by Leerink Swann Nov 23, 2009 Bank Lowers Estimate, Valuation on Illumina's Stock Jul 16, 2009 Wall Street Analyst Survey Finds Mass Specs the Top Priority for Capital Equipment Spending Premium Load More Breaking News Delic Partners With GT Research for Genetic Analysis of Cannabis, Psychedelic Mushrooms Indivumed, Biognosys Expand Partnership to Offer Immunopeptidomics Insights Multiomic Study Identifies Drivers of Severe COVID-19 in Patients Under 50 Without Comorbidities Yourgene H1 2022 Revenues More Than Double Gencove Raises $10M in Series A Financing Blueprint Genetics, BioMarin to Offer Genetic Testing for Skeletal Dysplasia in Europe, Middle East The Scan Should've Been Spotted Sooner Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier. For Martian Fuel Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo. To Boost Rapid Testing The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests. PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.